[Synergistic activity and clinical efficacy of fosfomycin and ciprofloxacin combination treatment for soft tissue infection caused by carbapenemase-producing Enterobacter cloacae]

Enferm Infecc Microbiol Clin. 2017 Feb;35(2):135-136. doi: 10.1016/j.eimc.2016.05.009. Epub 2016 Jun 27.
[Article in Spanish]
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Amikacin / therapeutic use
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Proteins / adverse effects*
  • Ciprofloxacin / administration & dosage
  • Ciprofloxacin / therapeutic use*
  • Colonic Diseases / complications
  • Drug Synergism
  • Drug Therapy, Combination
  • Enterobacter cloacae / drug effects
  • Enterobacter cloacae / isolation & purification*
  • Enterobacteriaceae Infections / drug therapy*
  • Enterobacteriaceae Infections / etiology
  • Female
  • Fosfomycin / administration & dosage
  • Fosfomycin / therapeutic use*
  • Hernia, Abdominal / surgery
  • Herniorrhaphy
  • Humans
  • Intestinal Fistula / complications
  • Minocycline / analogs & derivatives
  • Minocycline / therapeutic use
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / etiology
  • Postoperative Complications / microbiology
  • Prosthesis-Related Infections / drug therapy
  • Prosthesis-Related Infections / microbiology
  • Soft Tissue Infections / drug therapy*
  • Soft Tissue Infections / microbiology
  • Surgical Mesh / adverse effects
  • Tigecycline
  • beta-Lactamases / adverse effects*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Fosfomycin
  • Ciprofloxacin
  • Tigecycline
  • Amikacin
  • beta-Lactamases
  • carbapenemase
  • Minocycline